Case Western Reserve researchers use AI with routine CT scans to predict how well lung cancer patients will respond to expensive treatment based off changes in texture patterns inside and outside the tumor.
Scientists from the Case Western Reserve University digital imaging lab, already pioneering the use of Artificial Intelligence (AI) to predict whether chemotherapy will be successful, can now determine which lung-cancer patients will benefit from expensive immunotherapy.
And, once again, they’re doing it by teaching a computer to find previously unseen changes in patterns in CT scans taken when the lung cancer is first diagnosed compared to scans taken after the first 2-3 cycles of immunotherapy treatment. And, as with previous work, those changes have been discovered both inside—and outside—the tumor, a signature of the lab’s recent research.
“This is no flash in the pan—this research really seems to be reflecting something about the very biology of the disease, about which is the more aggressive phenotype, and that’s information oncologists do not currently have,” said Anant Madabhushi, whose Center for Computational Imaging and Personalized Diagnostics (CCIPD) has become a global leader in the detection, diagnosis and characterization of various cancers and other diseases by meshing medical imaging, machine learning and AI.
Currently, only about 20% of all cancer patients will actually benefit from immunotherapy, a treatment that differs from chemotherapy in that it uses drugs to help your immune system fight cancer, while chemotherapy uses drugs to directly kill cancer cells, according to the National Cancer Institute.
Madabhushi said the recent work by his lab would help oncologists know which patients would actually benefit from the therapy, and who would not.
“Even though immunotherapy has changed the entire ecosystem of cancer, it also remains extremely expensive—about $200,000 per patient, per year,” Madabhushi said. “That’s part of the financial toxicity that comes along with cancer and results in about 42% of all new diagnosed cancer patients losing their life savings within a year of diagnosis.”
Having a tool based on the research being done now by his lab would go a long way toward “doing a better job of matching up which patients will respond to immunotherapy instead of throwing $800,000 down the drain,” he added, referencing the four patients out of five who will not benefit, multiplied by annual estimated cost.
New research published
The new research, led by co-authors Mohammadhadi Khorrami and Prateek Prasanna, along with Madabhushi and 10 other collaborators from six different institutions (see list, below) was published this month in the journal Cancer Immunology Research.
Khorrami, a graduate student working at the CCIPD, said one of the more significant advances in the research was the ability of the computer program to note the changes in texture, volume and shape of a given lesion, not just its size.
“This is important because when a doctor decides based on CT images alone whether a patient has responded to therapy, it is often based on the size of the lesion,” Khorrami said. “We have found that textural change is a better predictor of whether the therapy is working.
“Sometimes, for example, the nodule may appear larger after therapy because of another reason, say a broken vessel inside the tumor—but the therapy is actually working. Now, we have a way of knowing that.”
Prasanna, a postdoctoral research associate in Madabhushi’s lab, said the study also showed that the results were consistent across scans of patients treated at two different sites and with three different types of immunotherapy agents.
“This is a demonstration of the fundamental value of the program, that our machine-learning model could predict response in patients treated with different immune checkpoint inhibitors,” he said. “We are dealing with a fundamental biological principal.”
Prasanna said the initial study used CT scans from 50 patients to train the computer and create a mathematical algorithm to identify the changes in the lesion. He said the next step will be to test the program on cases obtained from other sites and across different immunotherapy agents. This research recently won an ASCO 2019 Conquer Cancer Foundation Merit Award.
Additionally, Madabhushi said, researchers were able show that the patterns on the CT scans which were most associated with a positive response to treatment and with overall patient survival were also later found to be closely associated with the arrangement of immune cells on the original diagnostic biopsies of those patients.
This suggests that those CT scans actually appear to capturing the immune response elicited by the tumors against the invasion of the cancer—and that the ones with the strongest immune response were showing the most significant textural change and most importantly, would best respond to the immunotherapy, he said.
Madabhushi established the CCIPD at Case Western Reserve in 2012. The lab now includes nearly 60 researchers.
Some of the lab’s most recent work, in collaboration with New York University and Yale University, has used AI to predict which lung cancer patients would benefit from adjuvant chemotherapy based on tissue-slide images. That advancement was named by Prevention Magazine as one of the top 10 medical breakthroughs of 2018.
The Latest Google Headlines on:
The Latest Bing News on:
- New Drug Fusing Chemotherapy And Immunotherapy Can Fight Deadliest Cancerson November 21, 2020 at 10:00 pm
Researchers at Harvard’s Wyss Institute have developed a novel treatment methodology, combining chemotherapy and immunotherapy, and they’ve seen it attack Triple-Negative breast cancer.
- Immunotherapy Pioneer Prof. Carl H. June Joins AC Immune’s Board of Directorson November 20, 2020 at 5:42 am
Prof. June is a world authority on immune tolerance and adoptive immunotherapy. Appointment re affirm s AC Immune’s scien tific leadership in neurodegeneration. LAUSANNE, Switze ...
- Insights on the Allergy Immunotherapy Worldwide Industry to 2024 - Increasing Level of Air Pollution is Driving Growthon November 20, 2020 at 3:52 am
The "Global Allergy Immunotherapy (AIT) Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024 Edition)" report has been added to ResearchAndMarkets.com's offering. This report provides ...
- Sometimes Tumors Vanish, but Improvements Still Needed for CAR T-Cell Immunotherapyon November 19, 2020 at 12:35 pm
Patrick Reagan, M.D., looks at the data on his computer screen and a rare grin spreads across his face. His most recent study results for patients with end-stage mantle cell lymphoma show that an ...
- Seattle biotech firm Umoja Biopharma raises $53M as it tackles unique approach to immunotherapyon November 19, 2020 at 11:59 am
Umoja Biopharma raised $53 million to expand development of its CAR T-cell immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients.
- Computational method could predict immunotherapy response in patients with advanced melanomaon November 19, 2020 at 7:21 am
A computational method that combines clinicodemographic variables with deep learning of pre-treatment histology images could predict response to immune checkpoint blockade among patients with advanced ...
- Allergy Immunotherapy Market Size growing at 10.85% CAGR by 2027on November 19, 2020 at 6:41 am
Global Allergy Immunotherapy Market is valued approximately USD 2.9 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 10.85 % over the forecast period 2020-2027.
- Another side to cancer immunotherapy? Scientists investigate intratumoral B cellson November 19, 2020 at 4:11 am
Immunotherapies have transformed the treatment of several types of cancer over the last decade. Yet they focus on reactivating one arm of the immune system: cytotoxic T cells, which sniff out and kill ...
- Study identifies patients with lung cancer most likely to respond to immunotherapyon November 16, 2020 at 8:02 am
Scientists are beginning to unravel one of the biggest challenges with immunotherapy: why some people with cancer respond to the treatment, while others may not respond at all.
- Immunotherapy combination shrinks rare angiosarcoma tumors in 25% of patientson November 15, 2020 at 6:02 pm
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute's Division of Cancer Diagnosis and Treatment, part of the National Institutes of ...
The Latest Google Headlines on:
Artificial intelligence diagnostics
The Latest Bing News on:
Artificial intelligence diagnostics
- A new kind of artificial intelligence provides breakthrough in breast cancer diagnosison November 20, 2020 at 6:58 am
State-of-the-art technology which helps doctors more accurately diagnose breast cancer has been hailed as a breakthrough by the US Food & Drugs Administration (FDA) for its exceptional potential ...
- Artificial Intelligence in Diagnostic Market Register Growth 33.2% by 2027on November 19, 2020 at 7:18 am
Precedence Research, Recently Published Report on " Artificial Intelligence in Diagnostics Market (By Component: Hardware, Software and Services; By Diagnosis Type: Radiology, Pathology, Cardiology, ...
- Joint Artificial Intelligence Center Has Substantially Grown To Aid The Warfighteron November 18, 2020 at 5:31 pm
It was just two years ago when the Joint Artificial Intelligence Center was created to grab the ... and distribution of safe and effective vaccines, therapeutics, and diagnostics to counter COVID-19 ...
- Artificial intelligence for the detection of vertebral fractures on plain spinal radiographyon November 18, 2020 at 11:17 am
Vertebral fractures (VFs) cause serious problems, such as substantial functional loss and a high mortality rate, and a delayed diagnosis may further worsen the prognosis. Plain thoracolumbar ...
- Roche Canada Launches National Artificial Intelligence Centre of Excellenceon November 18, 2020 at 6:31 am
Roche partners with AI leaders Amii, Mila and the Vector Institute to drive digital transformation in health MISSISSAUGA, ON, Nov. 18, 2020 /CNW/ ...
- Leading pathology laboratories deploy tele-diagnostics with Philips during the COVID-19 pandemicon November 18, 2020 at 1:00 am
Pathology laboratories around the globe fully digitize tumor tissue samples to maintain the patient diagnostic experience while providing for staff ...
- Prima-Temp Awarded Groundbreaking Patent Using Artificial Intelligence For Ovulation Predictionon November 17, 2020 at 7:00 am
Temp, Inc., a leader in developing digital health solutions through chronobiology, has been awarded a patent recognizing its ...
- Dekel Gelbman Joins Day Zero Diagnostics as Senior Vice President of Business Development and Strategyon November 17, 2020 at 5:01 am
Day Zero Diagnostics Inc., an infectious disease diagnostics company utilizing genome sequencing and machine learning to combat the rise of antibiotic-resistant infections, today announced the ...
- Hologic Announces CE Mark of the Genius™ Digital Diagnostics System for Cervical Cancer Screeningon November 16, 2020 at 11:06 pm
(Nasdaq: HOLX) announced today that its new Genius™ Digital Diagnostics System is now CE marked in Europe. Genius Digital Diagnostics is the first digital cytology platform to combine a new artificial ...
- Aarhus University links brain research and artificial intelligence in new centreon November 16, 2020 at 8:01 am
IBrain, a new cross-disciplinary centre at Aarhus University, aims at developing new brain interfacing technologies enabled by novel AI hardware. The centre - the first of its kind in Denmark - brings ...